A nanocarrier Approach for Oral Peptide Delivery: Evaluation of Cell‐Penetrating Peptide Modified Liposomal Formulations in Dogs

Oral delivery of peptides is severely limited by their instability and poor absorption in the gastro-intestinal tract. In contrast to co-administration strategies using medium-chain fatty acids, which recently gained regulatory approval with low oral bioavailabilities ≤ 1% (Rybelsus® Mycapssa®), efforts clinically implement systems based on nanocarriers have not been successful date. The approved drug-delivery formulations show fairly accurate correlation between clinical results non-rodent mammal bioavailability, including Beagle dogs for Rybelsus®, indicating that represent a translationally relevant model. this study, we report nanocarrier formulation administration peptide therapeutics systemic targets consisting liposomes decorated cyclic cell-penetrating (CPP), significantly increased bioavailability dogs. This was optimized glyco-peptide vancomycin, resulted considerable 3.9 %. Further, system large linear therapeutic exenatide 20-fold, consistently achieved effective plasma concentrations article protected copyright. All rights reserved